Health Catalyst to Participate in Upcoming Investor Conferences
SOUTH JORDAN, Utah, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of...
Year: 2021
Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE
ZUG, Switzerland, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company focused on the discovery and development...
HMS Reports Fourth Quarter and Full Year 2020 Financial Results
FY'20 Total Revenue of $673.3 Million, +7.5% vs. FY'19FY'20 Net Income of $70.1 Million, -19.6% vs. FY'19FY'20 GAAP EPS of...
Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on...
HTG Concludes Feasibility Testing & Releases Second White Paper for its Planned Whole Transcriptome Panel Using HTG EdgeSeq Technology
TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose...
Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day®
WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on...
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent
San Francisco, CA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce...
Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical...
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical...
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it...
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple...
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on...
Streamline Health Announces Pricing of Upsized $14 Million Public Offering of Common Stock
ATLANTA, GA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM) (“Streamline Health”), provider of the eValuator™...
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN...
Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain
PORTLAND, Ore., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf,” “GLH” or...
Crescent European Specialty Lending Announces Refinancing for Leading Contract Research Organization Avania
LONDON & LOS ANGELES--(BUSINESS WIRE)--Crescent Capital Group LP, a leading alternative asset management firm, announced today that its European Specialty...
Glaukos Announces Positive Phase 3 Trial Results for iLink™ Epi-on Investigational Therapy That Met the Primary Efficacy Endpoint
Study Met Primary Efficacy Endpoint with Statistically Significant Improvement in Maximum Corneal Curvature at 6 Months Epi-on Treatment Demonstrated the...
Axonics® Reports Fourth Quarter and Fiscal Year 2020 Results
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable...
Glaukos Corporation Announces Fourth Quarter and Full Year 2020 Financial Results
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the...
Axonics® Expands into Stress Urinary Incontinence with the Acquisition of Bulkamid®
Combination creates a global leader for incontinence solutions Acquisition of Bulkamid is expected to be immediately accretive to Axonics IRVINE,...